South Korean investment firm SK Holdings has made a move on the U.S. with a deal to buy CDMO AMPAC.
Biogen and Eisai's anti-amyloid candidate shows promise; Otsuka signs two M&A deals; Samsung BioLogics faces criminal probe over Biogen JV agreement.
Mylan's price for its biosimilar of Amgen’s Neulasta has the potential to transform the biosimilar landscape, industry watchers say.
Though Trump convinced Pfizer to delay its planned price increases, Celgene, Roche and Novo have gone through with their own increases in July.
Sen. Ron Wyden wants to know more about why Pfizer CEO Ian Read agreed to defer the company's July price hikes.
A trial in a Delaware Court this week will determine if Fresenius can cancel its $4.3 billion buyout of competitor Akorn.
South Korean regulators have ruled on a case of alleged accounting violations at Samsung BioLogics and sent their findings to prosecutors.
With Johnson & Johnson's diabetes drug Invokana going up against two longtime rivals in China, the company is ramping things up.
Women put their own health on the back burner and don't have time to listen to health info, a new study says, making pharma's marketing job…
Pfizer’s latest overhaul sets biosimilars and hospital drugs alongside innovative products, where they can get brand-level attention.
